A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome

被引：0
|
作者：
Tadmor, Tamar [1 ,2 ]
Benjamini, Ohad [3 ]
Goldschmidt, Neta [4 ]
Kreiniz, Natalia [2 ]
Bairey, Osnat [5 ]
Harel, Reut [6 ]
Inbar, Tsofia [7 ]
Wolach, Ofir [8 ,9 ]
Herishanu, Yair [10 ]
机构：
[1] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel
[2] Bnai Zion Med Ctr, Hematol, Haifa, Israel
[3] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel
[4] Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel
[5] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[6] Emek Med Ctr, Dept Hematol, Afula, Ein Dor, Israel
[7] Rambam Hlth Care Campus, Dept Hematol & Bone Marrow Transplantat, Haifa, Israel
[8] Rabin Med Ctr, Inst Hematol, Davidoff Canc Ctr, Petah Tiqwa, Israel
[9] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[10] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185569
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma
    Othman, Tamer
    Rosenberg, Aaron S.
    Timmerman, John
    Heyman, Benjamin
    Abdulhaq, Haifaa
    Tuscano, Joseph M.
    BLOOD, 2022, 140 : 11954 - 11955
  • [2] A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.
    Montillo, Marco
    Rossi, Davide
    Zucca, Emanuele
    Frustaci, Anna Maria
    Pileri, Stefano
    Cavalli, Franco
    Tedeschi, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study
    Handunnetti, Sasanka M.
    Khot, Amit
    Anderson, Mary Ann
    Blombery, Piers
    Burbury, Kate
    Ritchie, David
    Hicks, Rodney J.
    Birbirsa, Besiat
    Bressel, Mathias
    Di Iulio, Juliana
    Westerman, David Alan
    Lade, Stephen
    Roberts, Andrew W.
    Seymour, John F.
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [4] PHASE-II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MILACEMIDE (CP1552S) IN THE TREATMENT OF COMPLEX PARTIAL SEIZURES IN ADULT PATIENTS
    NORTON, LC
    LAXER, KD
    SCHOMER, D
    OSBORN, P
    EPILEPSIA, 1986, 27 (05) : 648 - 648
  • [5] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Abruzzo, Lynne V.
    Andersen, Barbara L.
    Awan, Farrukh T.
    Bhat, Seema A.
    Dean, Allison
    Lucas, Margaret
    Banks, Christin
    Grantier, Cara
    Heerema, Nyla A.
    Lozanski, Gerard
    Maddocks, Kami J.
    Valentine, Thomas R.
    Weiss, David M.
    Jones, Jeffrey A.
    Woyach, Jennifer A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +
  • [6] SAFETY AND EFFICACY OF TOREMIFENE IN BREAST-CANCER PATIENTS - A PHASE-II STUDY
    VALAVAARA, R
    PYRHONEN, S
    HEIKKINEN, M
    RISSANEN, P
    BLANCO, G
    NORDMAN, E
    TASKINEN, P
    HOLSTI, LR
    HAJBA, A
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 36 (03): : 229 - 231
  • [7] Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study
    Metzgeroth, Georgia
    Walz, Christoph
    Erben, Philipp
    Popp, Helena
    Schmitt-Graeff, Annette
    Haferlach, Claudia
    Fabarius, Alice
    Schnittger, Susanne
    Grimwade, David
    Cross, Nicholas C. P.
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Reiter, Andreas
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (05) : 707 - 715
  • [8] Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.
    Frustaci, Anna Maria
    Montillo, Marco
    Rossi, Davide
    Zinzani, Pier Luigi
    Motta, Marina
    Gaidano, Gianluca
    Quaresmini, Giulia
    Scarfo, Lydia
    Pietrasanta, Daniela
    Coscia, Marta
    Deodato, Marina
    Zamprogna, Giulia
    Cairoli, Roberto
    Stussi, Georg
    Zucca, Emanuele
    Pileri, Stefano
    Zenz, Thorsten
    Tedeschi, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome
    Crombie, Jennifer L.
    Tyekucheva, Svitlana
    Wang, Zixu
    Savell, Alexandra
    Brennan, Lisa
    Lowney, Jessica
    Francoeur, Karen
    Montegaard, Josie
    Kim, Austin I.
    Soumerai, Jacob D.
    Arnason, Jon E.
    Cruz, Allan Louie
    Berg, Sigrid
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2020, 136
  • [10] Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Miljkovic, Milos D.
    Muppidi, Jagan R.
    Portell, Craig A.
    Farah, Rafic
    Lee, Seung Tae
    Juanitez, Anna Marie
    Chou, Lydia L.
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Staudt, Louis
    Roschewski, Mark
    Wilson, Wyndham
    BLOOD, 2019, 134
12345